An Oral Pill for Angioedema Attacks: Relief in 1.3 Hours

Hereditary angioedema is a rare genetic disease that causes sudden swelling of the skin, the gut or the throat. Attacks are driven by bradykinin, a molecule that makes blood vessels leak, and a throat attack can be life threatening. People who have it usually carry an on demand treatment, most often an injection or an infusion. On October 8, 2026, The Lancet published RAPIDe-3, a phase 3 trial of an oral alternative: deucrictibant, a capsule that blocks the bradykinin B2 receptor.

How the trial worked

RAPIDe-3 was double blind and used a crossover design: each participant was meant to treat two separate attacks, one with a 20 mg capsule of deucrictibant and one with placebo, in a random order. That way, each person serves as their own comparison, which helps in a rare disease where large trials are hard to fill. It ran at 59 sites in 24 countries and enrolled adolescents from 12 years old and adults up to 75. Participants needed at least two attacks in the three months before screening and experience using standard on demand treatment.

The primary endpoint was the time to onset of symptom relief.

The target is not new. An injectable drug that blocks the same B2 receptor, icatibant, has been used for years and is injected under the skin during an attack. The Lancet paper's authors describe deucrictibant as potentially the first B2 blocker that can be swallowed, which is the point of the trial: the same mechanism, in a form that needs no needle.

The numbers

Between April 2024 and September 2025, 134 eligible people were randomized: 10 adolescents and 124 adults. Of these, 113 treated 201 attacks during the study. The primary analysis included the 88 participants who treated a pair of attacks, one with each treatment.

Relief started much sooner with the pill. The median time to onset of symptom relief was 1.28 hours with deucrictibant, against more than 12 hours with placebo (p<0.0001). Put simply, half the treated attacks began to ease within about an hour and a quarter, while on placebo most did not ease within the 12 hours measured.

Two other figures help read the enrollment. Adolescents were only 10 of the 134 randomized people, so the result says little specifically about teenagers. And 201 attacks across 113 people means some participants treated a single attack, which keeps them out of the paired analysis but inside the safety data.

Tolerability looked good in this trial. Fatigue was the only adverse event reported more than once within three days of treatment, by two participants, and one case was judged unrelated. No treatment related adverse event was severe or serious, and none led anyone to stop treatment.

Reading it carefully

Three details shape how far the result goes. First, funding: the paper lists Pharvaris, the company developing deucrictibant, as the funder. That is normal for a phase 3 trial and does not invalidate it, but it is the first thing a reader should know.

Randomization was stratified by age and by whether participants took long term preventive treatment, so the two sequences were balanced on the factors most likely to change how attacks behave. Because each person contributed both a treated and a placebo attack, the comparison removes differences between people, though not between attacks: a mild attack and a severe one can still land on different treatments.

Second, the denominator. A crossover analysis needs both attacks, so people who treated only one, or none, fall out. The analysis included 88 people, about two thirds of those randomized. That is built into the design and stated in the paper, but the effect is measured on the group who had two attacks during the study window, not on everyone enrolled.

Third, the comparator. Placebo is a fair test of whether the pill works, and the gap here is wide. It does not tell a patient or a doctor whether a capsule is as fast as an injection they already use. The endpoint is also the start of relief, not the full resolution of the attack, which the paper reports separately.

The Lancet ran a linked comment on the trial. For the general checklist behind these three questions, see how to read a health study in five minutes. This article is not medical advice; changes to an angioedema plan belong with the treating specialist.

I see the value of this trial in the route more than the number. A capsule in a pocket removes the step that delays many on demand treatments, which is preparing and giving an injection during an attack. The data show the pill works much faster than nothing. What patients will want next is a comparison with what they carry today, and data on throat attacks, where minutes matter most.